Postmastectomy radiotherapy in patients with T1-2N1 breast cancer: a single center experience and a meta-analysis
- 31.05.2023
- Research
Erschienen in:
- Verfasst von
- Meng Luo
- Yao Jin
- Chunjing Xu
- Huihui Chen
- Kun Zhang
- Qiang Chen
- Chencan Jin
- Jinglu Lu
- Jing Wang
- Jia Huang
- Hao Deng
- Weili Jin
- Shu Zheng
- Yiding Chen
- Jiaojiao Zhou
- Erschienen in
- Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2023
Abstract
Purpose
Postmastectomy radiotherapy (PMRT) in patients with T1–2N1 breast cancer is still controversial. This study was to evaluate the survival prognosis of T1-2N1 patients with or without PMRT.
Patients and methods
From January 2006 to May 2017, 2606 female breast cancer patients underwent mastectomy in our medical center, among whom 402 patients of T1-2N1 stage with or without PMRT were finally analyzed. The median follow-up duration was 59.5 months. The primary endpoint was overall survival (OS). The secondary endpoint was disease-free survival (DFS).
Results
In the study of our center, no statistically significant difference was observed between the T1-2N1 PMRT and non-PMRT subgroups for the 5-year OS (94.4% vs 95.4%, p = 0.667) and DFS (90.1% vs. 91.1%, p = 0.798). By the date of the last follow-up, 8.96% (n = 36) of the patients experienced any recurrence. Univariate analysis revealed that PMRT was not a prognostic factor for either OS (p = 0.667) or DFS (p = 0.798) in T1-2N1 patients. We then did a meta-analysis on the current treatment patterns, in which 2606 PMRT and 4281 non-PMRT T1-2N1 breast cancer patients with mastectomy were included. The meta-analysis showed that PMRT didn't improve the OS of the patients (HR = 0.85, p = 0.11), but patients with PMRT had better DFS than those in the non-PMRT group (HR = 0.62, p < 0.001).
Conclusion
PMRT did not affect the survival of T1-2N1 breast cancer patients who underwent mastectomy, suggesting that radiotherapy may be safely omitted for them.
Anzeige
- Titel
- Postmastectomy radiotherapy in patients with T1-2N1 breast cancer: a single center experience and a meta-analysis
- Verfasst von
-
Meng Luo
Yao Jin
Chunjing Xu
Huihui Chen
Kun Zhang
Qiang Chen
Chencan Jin
Jinglu Lu
Jing Wang
Jia Huang
Hao Deng
Weili Jin
Shu Zheng
Yiding Chen
Jiaojiao Zhou
- Publikationsdatum
- 31.05.2023
- Verlag
- Springer Berlin Heidelberg
- Erschienen in
-
Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335 - DOI
- https://doi.org/10.1007/s00432-023-04908-7
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
